February 14th 2025
Cell and gene therapies can be life-changing for patients with certain conditions, but the process of receiving them poses barriers for patients and caregivers that require multistakeholder solutions, according to a white paper from the National Pharmaceutical Council.
Adding Social Factors to Risk Adjustment Not Enough to Reach Health Equity, Paper Says
January 12th 2023To best improve health equity, population-based payment models should both incorporate social goals and increase payment for historically marginalized communities, a recent study has found.
Read More
Health Systems and Telemedicine Adoption for Diabetes and Hypertension Care
Small practices reduced their use of telemedicine during early stages of the COVID-19 pandemic. Technical support may help expand and maintain telemedicine in small practices.
Read More
Newer Drugs for Epilepsy Less Likely to Be Prescribed to Black, Latino Patients on Medicaid
January 11th 2023Patients with epilepsy on Medicaid insurance of Black, Latino, and Native Hawaiian and Other Pacific Island ethnicity were associated with lower odds of being on newer, second- and third-generation, antiseizure medications compared with White individuals.
Read More
Spotlighting Health Disparities for Black Americans With Multiple Myeloma and Potential Solutions
January 11th 2023Black Americans with multiple myeloma face disparities in incidence of disease, survival outcomes, and use of evidence-based treatment, which may be exacerbated by socioeconomic factors.
Read More
What We’re Reading: Biden to Extend PHE Once More; High Court Rejects Pharma Suits; 988 Calls Soar
January 10th 2023President Joe Biden expected to renew COVID-19 public health emergency (PHE) one more time; Bristol Myers Squibb and Pfizer are denied by the Supreme Court; funding for the 988 mental health helpline expands inclusivity efforts.
Read More
Disparities in Multiple Myeloma Treatment, Mortality Risk Observed Among Hispanic Americans
January 9th 2023Despite greater incidence of multiple myeloma (MM) reported among Hispanic Americans, these populations report less MM maintenance therapy, longer time from MM diagnosis to novel therapy initiation, and higher in-hospital mortality rates.
Read More
FDA’s Lecanemab Approval Will Raise Pricing, Access Challenges, Says Dr Alvaro Pascual-Leone
January 6th 2023The FDA’s approval of lecanemab for Alzheimer disease is very important, but there will remain significant challenges around pricing and access that will need to be addressed to deliver on the promise the therapy actually represents, said Alvaro Pascual-Leone, MD, PhD, of Harvard Medical School.
Watch
Developing a Framework to Address Health Inequities in Epilepsy
January 6th 2023A review explored the connection between 4 domains (structural, sociocultural, health care, and physiological) contributing to the persistence of inequities in epilepsy risk and outcomes in the United States, as well as key areas of intervention to promote health equity.
Read More
Improved Work-, Study-Related Productivity Shown With Tildrakizumab in Patients With Psoriasis
January 5th 2023Abstract findings presented at the 2022 American Academy of Dermatology Annual Meeting showed that patients with moderate to severe psoriasis achieved improvement in work-/study-related productivity with tildakizumab vs placebo after only 2 doses.
Read More
HHS updated guidance for states using Medicaid managed care to manage nonmedical needs; anxieties surrounding new variants rise amidst underreported COVID-19 cases in China, which defended its counts; public health campaigns try new strategies to increase trust and promote immunizations.
Read More
Michael Thompson on Steps Needed to Bolster Health Equity Initiatives in the Workplace
January 4th 2023Michael Thompson, president and CEO of the National Alliance of Healthcare Purchaser Coalitions (National Alliance), addressed the current state of health equity strategies in the workplace and how employers can better address inequities in their benefit designs, programs, and policies in the near future.
Watch
Dual-regimen abortion pills authorized for pharmacy sale by FDA; health professionals turn a critical eye to US concerns about COVID-19 in China while domestic cases rise here as vaccination rates drop; drug manufacturers are collectively raising prices early this month on medications from autoimmune treatments to shingles vaccines to cancer treatments.
Read More
The Chinese government warns of backlash for countries requiring COVID-19 testing of travelers from China; monoclonal antibody drugs show some promise against infectious diseases, but costs need to be lower; the role of FDA and Biogen in approving Alzheimer drug Aduhelm is detailed in a scathing Congressional committee report.
Read More
Dr Jessica Allegretti Explains Rebyota’s Mechanism of Action for the Prevention of Recurrent CDI
December 21st 2022Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, explained the mechanism of action for Rebyota, the first fecal transplant therapy approved by the FDA for the prevention of recurrent Clostridioides difficile infection (CDI) in individuals 18 years and older, following antibiotic treatment for recurrent CDI.
Watch
Dr Liz Lightstone: Lupus Nephritis Misconceptions Contributing to Underdiagnosis, Low-Value Care
December 15th 2022Liz Lightstone, MBBS, PhD, FRCP, professor of Renal Medicine for the Faculty of Medicine, Imperial College London, discussed how sexism and other factors cause certain symptoms of lupus nephritis to be overlooked, contributing to delays in diagnosis and care.
Watch
Racial Disparities Shown for Delayed Diagnosis, Dermatologic Care in Hidradenitis Suppurativa
December 13th 2022Non-White patients with hidradenitis suppurativa reported longer delay in diagnosis than their White counterparts. In addition, Black patients did not receive dermatologic care as early in their disease course as other racial groups.
Read More
DAA Therapy Linked With Improved Liver, Mortality Outcomes in Patients With Chronic Hepatitis C
December 12th 2022Use of direct-acting antiviral (DAA) treatment (without interferon) was shown to reduce liver and nonliver complications, as well as improve long-term overall survival among patients with chronic hepatitis C.
Read More
Organizational Capacity Among Hospitals in Medicare and Commercial Bundled Payments
A national survey demonstrated differences in organizational capacity between hospitals participating in Medicare bundled payment programs and those coparticipating in both Medicare and commercial bundled payment programs.
Read More